Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depemokimab versus mepolizumab or benralizumab in severe eosinophilic asthma
NL-OMON54219Phase 3Recruiting
- Sponsor
- GSK
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of depemokimab, mepolizumab and benralizumab in severe asthma and eosinophilic asthma (EA), sponsored by GSK. Primary endpoint: Annualized rate of clinically significant exacerbations. Started Apr 2022; status: recruiting.
02
Drugs
depemokimabmepolizumabbenralizumab
03
Conditions
severe asthmaeosinophilic asthma (EA)
Beyond the preview
Go deeper on NL-OMON54219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54219.